
The European Commission has approved RASONQUE (daraxonrasib), the first broad RAS-targeted oral medicine for adults with metastatic pancreatic adenocarcinoma who have had prior systemic therapy. This approval covers patients with or without identified RAS tumor mutations and is based on positive Phase 3 trial results showing significant survival benefits. Revolution Medicines is working with EU countries to enable patient access, though timing will vary due to national pricing and reimbursement processes. This marks a significant advancement in treatment options for a cancer type with historically poor prognosis and limited therapies.
Following the European Commission's approval of Revolution Medicines' RASONQUE for metastatic pancreatic cancer, the company's stock on Pluang is trading at USD 167.74 as of Nov 17, 2026 01:12 WIB, down 2.64% in the past day. Revolution Medicines holds a market cap of $37.25 billion on Pluang, with its 52-week price range between $67.75 and $221.15. The typical hold time for this stock on Pluang is 12 days.